SCHEMBL491072

SCHEMBL491072

O=C(O)C(Cc1cc(O)ccc1O)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.47
LCK P06239 4/20 0.47
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA7 P43166 2/20 0.45
CA9 Q16790 2/20 0.45
CA14 Q9ULX7 2/20 0.45
PTGS2 P35354 2/20 0.45
ALOX5 P09917 1/20 0.45
ALDH1A1 P00352 6/20 0.45
TDP1 Q9NUW8 4/20 0.45
MAPT P10636 4/20 0.45
RGS12 O14924 2/20 0.45
CAMKK2 Q96RR4 1/20 0.45
NOX4 Q9NPH5 1/20 0.45
KMT2A Q03164 4/20 0.43
ALOX15 P16050 4/20 0.43
HSD17B10 Q99714 4/20 0.43
USP2 O75604 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490958 0.84 TYR (0.54) CA12CA1CA2CA7CA9
SCHEMBL8540405 0.83 KDM4E (0.66) EGFRLCKPTGS2ALDH1A1TDP1
SCHEMBL5286425 0.83 KDM4E (0.66) EGFRLCKPTGS2ALDH1A1TDP1
Water SCHEMBL11769068 0.82 KDM4E (0.64) EGFRLCKPTGS2ALDH1A1TDP1
Water SCHEMBL11769062 0.82 KDM4E (0.64) EGFRLCKPTGS2ALDH1A1TDP1
SCHEMBL490495 0.79 CA12 (0.53) EGFRCA12CA1CA2CA7
SCHEMBL111318 0.77 EGFR (0.47) EGFRLCKPTGS2ALOX5ALDH1A1
SCHEMBL490623 0.77 ALOX15 (0.68) EGFRLCKPTGS2ALDH1A1TDP1
SCHEMBL490396 0.76 EGFR (0.55) EGFRLCKPTGS2ALOX5ALDH1A1
SCHEMBL5877825 0.75 GABRA1 (0.68) EGFRCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268293-B2 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2012-09-18 US disclosed
CN-101163659-B Antioxidants MERCK PATENT GMBH 2012-09-05 CN disclosed
US-8106233-B2 Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing MERCK PATENT GMBH (DE) 2012-01-31 US disclosed
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2008-07-17 US disclosed
US-20080152603-A1 Antioxidants SUSONITY Commercial GmbH (DE) 2008-06-26 US disclosed
CN-101163659-A Antioxidants MERCK PATENT GMBH (DE) 2008-04-16 CN disclosed
EP-1871339-A1 UV PROTECTION Merck Patent GmbH (DE) 2008-01-02 EP disclosed
EP-1871735-A1 ANTIOXIDANTS Merck Patent GmbH (DE) 2008-01-02 EP disclosed
WO-2006111233-A1 ANTIOXIDANTS MERCK PATENT GMBH (DE) 2006-10-26 WO disclosed
WO-2006111234-A1 UV PROTECTION MERCK PATENT GMBH (DE) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080152603-A1 Antioxidants GPX4, GPX1, CAT EGFR 4841/4885LCK 4728/4885CA12 3215/4885
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives HPD, HAAO, UGT1A6 EGFR 2455/4885LCK 4878/4885CA12 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.